Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension

Journal of Human Hypertension

Volumn 27, Issue 1, 2013, Pages 44-50

  Christogiannis, L G ^a   Kostapanos, M S ^a   Tellis, C C ^b   Milionis, H J ^a   Tselepis, A D ^b   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

amlodipine; hydrochlorothiazide; lipoprotein subfractions; low density lipoprotein particle size; valsartan

Indexed keywords

AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLORTHIAZIDE PLUS VALSARTAN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; DRUG SAFETY; FEMALE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; LOW DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PATIENT COMPLIANCE; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CHOLESTEROL; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PARTICLE SIZE; TETRAZOLES; TRIGLYCERIDES; VALINE;

EID: 84870826740     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2011.108     Document Type: Article

References (37)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
3. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
5. Oparil S, Weber M. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy. Postgrad Med 2009; 121: 25-39.
6. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.
7. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 2003; 23: 2155-2163.
8. Martinez-Martin FJ, Rodriguez-Rosas H, Peiro-Martinez I, Soriano-Perera P, Pedrianes-Martin P, Comi-Diaz C. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Hum Hypertens 2011; 25: 346-353.
9. Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 1998; 39: 1263-1273.
10. St-Pierre AC, Cantin B, Dagenais GR, Mauriège P, Bernard PM, Després JP et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25: 553-559.
11. Landray MJ, Sagar G, Muskin J, Murray S, Holder RL, Lip GY. Association of atherogenic low-density lipoprotein subfractions with carotid atherosclerosis. QJM 1998; 91: 345-351.
12. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006; 3: 144-153.
13. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23: 370-378.
14. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122: 133-141.
15. Karagiannis A, Tziomalos K, Anagnostis P, Gossios TD, Florentin M, Athyros VG et al. The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis. Curr Vasc Pharmacol 2010; 8: 792-803.
16. Sacks FM, Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP et al. A dietary approach to prevent hypertension: a review of the Dietary Approaches to Stop Hypertension (DASH) Study. Clin Cardiol 1999; 22: III6-II10.
17. Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol 2008; 590: 327-332.
18. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoproteinassociated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005; 51: 2264-2273.
19. Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007; 27: 2236-2243.
20. Weidmann P, de Courten M, Ferrari P, Bohlen L. Serum lipoproteins during treatment with antihypertensive drugs. J Cardiovasc Pharmacol 1993; 22: S98-105.
21. Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther 2010; 8: 793-802.
22. Wong MC, Jiang JY, Ali MK, Fung H, Griffiths S, Mercer SW. Antihypertensive drug class and dyslipidemia: risk association among Chinese patients with uncomplicated hypertension. J Hum Hypertens 2008; 22: 648-651.
23. Jounela AJ, Lilja M, Lumme J, Mö rlin C, Hoyem A, Wessel-Aas T et al. Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. Blood Press 1994; 3: 231-235.
24. Bakris GL, Smith AC, Richardson DJ, Hung E, Preston R, Goldberg R et al. Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study. J Hum Hypertens 2002; 16: 185-191.
25. Griffin BA. Lipoprotein atherogenicity: an overview of current mechanisms. Proc Nutr Soc 1999; 58: 163-169.
26. Ferrannini E, Galvan AQ, Santoro D, Natali A. Potassium as a link between insulin and the renin-angiotensin-aldosterone system. J Hypertens Suppl 1992; 10: S5-S10.
27. Biswas PN, Wilton LV, Shakir SW. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England. J Hum Hypertens 2002; 16: 795-803.
28. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008; 294: E15-E26.
29. Boquist S, Ruotolo G, Hellenius ML, Danell-Toverud K, Karpe F, Hamsten A. Effects of a cardioselective beta-blocker on postprandial triglyceride-rich lipoproteins, low density lipoprotein particle size and glucose-insulin homeostasis in middleaged men with modestly increased cardiovascular risk. Atherosclerosis 1998; 137: 391-400.
30. Hirano T, Yoshino G, Kashiwazaki K, Adachi M. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. Am J Hypertens 2001; 14: 908-913.
31. Saiki A, Ohira M, Endo K, Koide N, Oyama T, Murano T et al. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension. Diabetes Res Clin Pract 2006; 74: 242-248.
32. Stimpel M, Koch B, Oparil S. Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). Cardiology 1998; 89: 271-276.
33. Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A et al. 'European panel on low density lipoprotein (LDL) subclasses': a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9: 533-571.
34. Asztalos BFCL, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ. Highdensity lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004; 24: 2181-2187.
35. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005; 25: 2185-2191.
36. Valimaki M, Maass L, Harno K, Nikkila EA. Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol. Eur J Clin Pharmacol 1986; 30: 17-20.
37. Kostapanos MS, Milionis HJ, Filippatos TD, Christogiannis LG, Bairaktari ET, Tselepis AD et al. Dose-dependent effect of rosuvastatin treatment on HDLsubfraction phenotype in patients with primary hyperlipidemia. J Cardiovasc Pharmacol Ther 2009; 14: 5-13.